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Numerous transcription factors have been identified which have profound effects on developing neurons. A fundamental problem is to identify
genes downstream of these factors and order them in developmental pathways. We have previously identified 85 genes with changed expression in
the trigeminal ganglia of mice lacking Brn3a, a transcription factor encoded by the Pou4f1 gene. Here we use locus-wide chromatin
immunoprecipitation in embryonic trigeminal neurons to show that Brn3a is a direct repressor of two of these downstream genes, NeuroD1 and
NeuroD4, and also directly modulates its own expression. Comparison of Brn3a binding to the Pou4f1 locus in vitro and in vivo reveals that not
all high affinity sites are occupied, and several Brn3a binding sites identified in the promoters of genes that are silent in sensory ganglia are also
not occupied in vivo. Site occupancy by Brn3a can be correlated with evolutionary conservation of the genomic regions containing the recognition
sites and also with histone modifications found in regions of chromatin active in transcription and gene regulation, suggesting that Brn3a binding
is highly context dependent.
© 2007 Elsevier Inc. All rights reserved.Keywords: Brn3; Brn3a; Pou4f1; NeuroD1; NeuroD4; POU domain; Chromatin immunoprecipitation; Trigeminal ganglionIntroduction
The development of any organ system requires the
coordinated regulation of gene expression to generate increas-
ingly specialized cell types. Tissue-specific gene expression is
regulated primarily at the transcriptional level, by DNA-binding
transcription factors that are expressed at key decision points in
developmental processes. No tissue presents a more complex
problem in the developmental regulation of gene expression
than the vertebrate nervous system, where transcription factors
of several structural families have been shown to have profound
effects on the development of the spinal cord, brainstem,
forebrain, retina, and peripheral sensory and autonomic ganglia
(Helms and Johnson, 2003; Marquardt, 2003; Shirasaki and
Pfaff, 2002; Zaki et al., 2003). In each of these areas, loss of
regulatory function may lead to the agenesis of a class of
neurons, respecification of neuronal phenotypes, aberrant cell
migration or axon growth, or abnormal cell death.⁎ Correspondence author. Fax: +1 858 534 7653.
E-mail address: eturner@UCSD.edu (E.E. Turner).
0012-1606/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.10.050Although the importance of neuron-specific transcriptional
regulation is clear, in most cases the downstream targets of
transcription factors with established roles in neural develop-
ment remain unknown. Recent studies using expression arrays
have been successful in defining multiple regulatory targets for
a few of these factors in the developing retina, cerebellum, and
sensory system (Eng et al., 2004; Gold et al., 2003; Livesey et
al., 2000; Mu et al., 2004). However, in each of these studies
several of the regulated genes also encode transcription factors,
leading to significant uncertainty about which of the down-
stream genes are directly regulated and which are secondary
targets.
The direct target genes of a developmental transcription
factor are expected to contain binding sites for that factor within
cis-acting regulatory domains, typically but not necessarily
located in upstream or intronic sequences near the transcrip-
tional start site of that gene. However, the short recognition
sequences of monomeric or dimeric transcription factors occur
frequently in the genome, and are not in themselves sufficient to
restrict transcriptional regulation to a small number of tissue-
specific genes. Therefore, some mechanism for the further
restriction of transcriptional activity in vivo is required.
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act at their recognition sites only when they occur in a specific
context, and/or in the presence of other cell-specific DNA-
binding factors, a concept which has been referred to as a
“combinatorial code” for cell-specific transcription. However,
at present there are no general predictive algorithms for
recognizing functional binding sites in vertebrates, and these
relationships must be determined empirically.
We have been engaged in studies of the Pou4 or “Brn3” class
of transcription factors, consisting in vertebrates of Brn3a
(Pou4f1, Brn3.0), Brn3b (Pou4f2, Brn3.2), and Brn3c (Pou4f3,
Brn3.1). Brn3a is expressed throughout the peripheral sensory
nervous system and at multiple levels of the CNS, and targeted
disruption of the Pou4f1 locus results in excessive apoptosis in
several regions of the embryonic brain, marked defects in
sensory axon growth, and neonatal lethality (Eng et al., 2001;
McEvilly et al., 1996; Xiang et al., 1996). Brn3b and Brn3c are
more restricted in their expression, and null mutations of these
genes result in viable mice with more specific defects in the
development of the retina and the inner ear, respectively
(Erkman et al., 2000; Gan et al., 1996; Xiang et al., 1997).
The POU transcription factor class is characterized by a
bipartite DNA binding domain, consisting of a POU-specific
domain and a POU homeodomain, which together recognize an
extended DNA site (Phillips and Luisi, 2000). Biochemical and
transfection studies have shown that the vertebrate and
invertebrate members of the Pou4 subclass bind to a consensus
sequence consisting of ATAATTAATand minor variants thereof
(Gruber et al., 1997; Rhee et al., 1998). Genetic studies have
demonstrated that Brn3a regulates its own expression in sensory
neurons via a cluster of such sites residing approximately 5.5 kb
upstream from the Pou4f1 transcriptional start site (Trieu et al.,
2003; Trieu et al., 1999).
Two recent studies have begun to ascertain the transcrip-
tional targets of the Pou4 factors in the developing nervous
system, using expression arrays with partial genomic coverage
to assay global gene expression in the sensory ganglia and retina
of mice lacking Brn3a and Brn3b, respectively (Eng et al., 2004;
Mu et al., 2004). In both cases, the majority of regulated
transcripts belong to gene families with known or potential roles
in neurodevelopment, although only a few shared targets were
identified. Extrapolating these results to the entire transcriptome
suggests that the Pou4 factors regulate on the order of 102
downstream transcripts in a single tissue type at a given
developmental stage, including both direct and indirect targets.
In the present study, we use locus-wide, real-time chromatin
immunoprecipitation assays in embryonic sensory neurons to
better understand the relationship between Brn3a and its
transcriptional targets. These experiments show that Brn3a is
a direct repressor of the bHLH genes NeuroD4 (Math3) and
NeuroD1, via consensus Brn3a binding sites. Brn3a also
interacts directly with its own autoregulatory enhancer via
relatively weak sites. In all three loci, most occupied Brn3a
recognition sites occur in regions of local conservation between
the mouse and human genomes. Examination of histone H3
acetylation and H3-lys4 dimethylation across the target gene
loci reveals that site occupancy by Brn3a also correlates withthese markers of transcriptionally active chromatin. Brn3a
binding sites in the promoters of genes which are not transcribed
in sensory ganglia and are de-acetylated in vivo appear to be
generally unoccupied by Brn3a. Together these findings begin
to illuminate the genomic context in which Brn3a regulates its
downstream targets in sensory neurons.
Materials and methods
Bioinformatic analysis
Interspecies conservation was determined by comparing mouse and human
genomic sequences using the pairwise LAGAN function from the LAGAN
Alignment Toolkit Web site (Brudno et al., 2003). Alignments were visualized
using VISTA software (Mayor et al., 2000), and the percent conservation
between the mouse and human sequences was mapped using a 100 base pair
moving window.
Brn3a chromatin immunoprecipitation
Embryos for ChIP assays were generated from timed matings of ICR mice
and staged according to the method of Theiler (Theiler, 1972). Trigeminal
ganglia were dissected from E13.5 embryos and fixed in 4% paraformaldehyde
for 30 min, then quenched with 150 mM glycine. The fixed tissue was washed
with PBS and stored at −80 °C until analysis.
Selection of Brn3a complexes from embryonic sensory ganglia was
performed by a modification of a widely used procedure (Luo et al., 1998).
For each analysis, 60 fixed ganglia were pooled and suspended in lysis buffer
containing 50 mM Tris–HCl, pH 8.1, 1% Triton-X-100, 10 mM EDTA, 1 mM
AEBSF, and a proprietary protease inhibitor mix (1X Complete Mini, Roche,
used according to instructions). An oligonucleotide containing a high affinity
Brn3a binding site was added to a final concentration of 0.5 μM to suppress any
artifactual Brn3a–chromatin interactions which may form during the homo-
genization process. The oligonucleotides GATCTCTCCTGCATAATTAAT-
TACCCCCGGAT and GATCCGGGGGTAATTAATTATGCAGGAGAGAT
were annealed to form the double stranded oligonucleotide competitor which
contains the previously described consensus Brn3a binding site ATAATTAAT
(Gruber et al., 1997). Ganglia were incubated in lysis buffer at 4° on a rotating
platform for 10 min. Chromatin was then fragmented to an average size of 500
base pairs by sonication, and insoluble cellular debris was removed by
centrifugation. The supernatant containing fragmented chromatin was diluted in
15 mM Tris–HCl, pH 8.1 with 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100,
and protease inhibitor mix. An unselected (“input”) sample of 10% of the total
homogenate was removed prior to antibody selection.
Selection of Brn3a protein-containing complexes was performed using
50 μL of sheep anti-rabbit IgG magnetic beads (Dynal M-280), pre-loaded with
10 μg of rabbit anti-Brn3a antibody. In order to reduce non-specific background,
the chromatin sample was pre-cleared using the magnetic beads with the
secondary antibody alone. The sample was then incubated overnight with Brn3a
antibody-coupled beads to select the Brn3a protein-containing chromatin
complexes. The selected complexes were washed with 20 mM Tris–HCl, pH 8.1
with 150 mM NaCl, 2 mM EDTA, and 1% Triton-X-100, followed by two
washes with 10 mM Tris–HCl, pH 8.1 with 0.25 M LiCl, 1% IGEPAL, 1%
Deoxycholate, and 1 mM EDTA. The final wash was performed in 20 mM Tris–
HCl, pH 8.1 with 150 mM NaCl and 2 mM EDTA. Each wash was performed
for 5 min at room temperature. DNA was extracted from both the antibody–
chromatin complexes and input sample by heating in 0.1 M NaHCO3 with
200 mM NaCl and 1% SDS at 65° for 4 h with constant shaking. The input and
selected samples were then digested with proteinase K, extracted with phenol/
chloroform, and precipitated with ethanol.
Histone H3 chromatin immunoprecipitation
Modified histone H3 ChIP experiments were performed using rabbit anti-
acetylated histone H3 antibody (Upstate Biotechnology, Inc., catalog no. 06-
599), which recognizes histone H3 acetylated at lys9 and lys14, and rabbit anti-
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protocol described above was slightly altered for use with antibodies against
modified histones. For each selection, 50 μg of anti-histone antibody was
coupled to 250 μL of anti-rabbit IgG magnetic beads, and the lysis buffer
contained 50 mM Tris–HCl, pH 8.1 with 10 mM EDTA and 1% SDS. The
selected complexes were washed for five min at room temperature with each of
the following solutions: 20 mM Tris–HCl, pH 8.1 with 150 mM NaCl, 2 mM
EDTA, 0.1% SDS, and 1% Triton-X-100; 20 mM Tris–HCl, pH 8.1 with
500 mM NaCl, 2 mM EDTA, 0.1% SDS, and 1% Triton-X-100; 10 mM Tris–
HCl, pH 8.1 with 1 mM EDTA, 0.25 M LiCl, 1% NP-40, and 1% deoxycholate.
Salt and detergent were removed by washing twice with TE, pH 8.
Real-time locus-wide PCR analysis
Chromatin fragments recovered from the immunoprecipitated and input
samples were then assayed by real-time PCR using an ABI 7300 thermocycler
and SYBR Green fluorimetric detection. Selected and unselected samples were
run in parallel in a 96-well plate format, and the enrichment of immunopre-
cipitated chromatin fragments was assayed by the cycle-threshold difference
method (Livak and Schmittgen, 2001). To screen an entire gene locus,
oligonucleotide pairs were designed at 500–1000 bp intervals throughout the
region. Because the selected chromatin was sheared to an average size of
approximately 500 bp, it was not necessary for the ChIP oligonucleotide pairs to
encompass the actual binding site to give a positive signal, and as expected the
ChIP signal decayed over about 1 kb in either direction from the site. When
enrichment was seen in a region with the screening set of oligonucleotides,
further independent oligonucleotide pairs were designed in the interval to
confirm the result in subsequent assays.
Real-time PCR signals were measured using the “cycle threshold”, or Ct
parameter, which is the number of cycles required for the amplification product
to reach an arbitrary level of fluorescence intensity (threshold). The threshold is
set in the log-linear range of the product generation curve, assuring that the
quantitation of the PCR products occurs in the logarithmic phase of
amplification. A further advantage of the method is that the small amplicons
used for real-time PCR amplify much more reliably than products which are
designed to be quantitated by gel electrophoresis. The Ct value is related
logarithmically to the initial abundance of the target sequence in the sample in
that more abundant targets will reach the threshold faster, and yield a lower Ct
value. Because product formation approximately doubles with each cycle in the
linear range of amplification, a Ct difference of one cycle represents a 2-fold
difference in starting template.
For each PCR amplicon, signals from the unselected (“input”) and antibody-
selected DNA samples were then compared using the cycle threshold difference
(ΔCt) method. AΔCt value was calculated for each amplicon by subtracting the
Ctselected from the Ctinput signal (ΔCt=Ctinput−Ctselected). A significant
advantage of this method is that for each primer pair, a selected sample is
compared directly to its unselected control, which differs only by the antibody
selection process. Potentially confounding factors such as small differences in
the PCR amplification efficiency of different primer pairs are eliminated in this
comparison.
The ΔCt assays for each pool of anti-Brn3a selected material were
normalized to a baseline (1-fold enrichment) determined using the average ΔCt
value (ΔCtcontrol) for ten primer pairs spanning the Alb-1 (albumin) gene, which
was chosen for this purpose because is not transcribed in the nervous system.
Little variation was observed across flanking, promoter, intronic, and translated
sequences in ChIP selection assays of the Alb-1 locus (Supplementary Fig. 1A).
Anti-histone selected assays were normalized to the average ΔCt value of two
amplicons in the Alb-1 promoter region which showed enrichment values
representative of the whole locus (Supplementary Fig. 1B). A second method of
normalizing the ΔCt values, using primer pairs to promoter regions of Mapt
(microtubule-associated protein tau) and Eno2 (neuron-specific enolase), which
exhibit tissue-specific expression in the nervous system, and Gapdh
(glyceraldehyde-3-phosphate dehydrogenase), which is expressed ubiquitously,
gave very similar results.
Fold enrichment values for target sequences bound by the selecting
antibodies, corresponding to the y-axis of the locus-ChIP plots, was calculated
using the following equation: E=2^(ΔCt−ΔCtcontrol). The statistical signifi-
cance (p-value) for ChIP selection at a given Brn3a binding site was calculatedusing fold enrichment values for all primer pairs located within 500 base pairs of
the binding site, compared to the enrichment values for the Alb-1 locus, using
two-sample, unequal variance t-tests. Very similar results were obtained when
the peaks of ChIP enrichment were compared to the intergenic baseline flanking
the same gene.
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assays were performed using probes generated
by PCR using radiolabeled primers, or with 32 base pair double-stranded
oligonucleotides containing Brn3a recognition sites (Supplementary Table 2), as
previously described (Gruber et al., 1997; Trieu et al., 1999). Full-coding Brn3a
protein was expressed in sf9 cells using a baculovirus expression system. Use of
alternate translation initiation sites resulted in some size heterogeneity of Brn3a/
DNA complexes in EMSA assays, but did not affect the C-terminal DNA-
binding domain of Brn3a.
Dissociation rates for Brn3a–DNA complexes were estimated by EMSA,
providing a rapid method for comparing the stability of Brn3a association with a
large number of binding sites. EMSAs were performed a 50-μl volume
containing 20 mM Tris (pH 8.0), 100 mM KCl, 5 mM MgCl2, 0.2 mM EDTA,
100 μg/ml of poly(dI-dC), 100 μg/ml BSA, 10% glycerol, and 1 mM
dithiothreitol. In these assays, Brn3a protein was incubated with a radiolabeled
DNA probe in EMSA binding cocktail for 20 min at 20 °C. Then, at 5 or 20 min
before the start of electrophoresis, 1×10−11 mol of an unlabeled high affinity
Brn3a oligonucleotide competitor, containing the consensus Brn3a binding site
ATAATTAAT, was added to the binding assay (consensus, Supplementary Table
2, Gruber et al., 1997). The relative quantities of Brn3a complexes remaining
after 5- and 20-min incubation with the oligonucleotide competitor were
determined from scanned autoradiograms using Image J software. The half-lives
of Brn3a complexes were determined based on first order kinetics.
Complex stability screening
In order to identify the most stable (highest affinity) Brn3a binding sites
within a large genomic region encompassing the Pou4f1 locus, we adapted a
protocol previously used to identify the Brn3a autoregulatory binding site
cluster (Trieu et al., 1999). A BAC clone containing 188 kb of mouse genomic
sequence surrounding the Pou4f1 gene (Clone ID: RP23_360a14, BACPAC
Resources Center) was sheared to an average size of 500 base pairs by
sonication, and the ends of the DNA fragments were repaired for A-T cloning
using mung bean nuclease and the addition of single 3′-dA residues using a
commercial tailing kit (Novagen).
Selection of the sheared, tailed BAC DNAwas performed using 15 μg of rabbit
anti-Brn3a antibody pre-incubated with 50 μL paramagnetic beads conjugated to
sheep anti-rabbit IgG (Dynal M-280). The coupled beads were then incubated with
20 μL of sf9 cell lysate containing full-coding Brn3a protein (described above),
rinsed, and incubated with 10 μg of sheared BAC DNA. Binding reactions were
performed in EMSA buffer as described above, except dI/dC was omitted.
Following the initial binding reaction, the beads were resuspended in binding buffer
containing 2 μM oligonucleotide competitor containing a Brn3a consensus binding
site and incubated for 10min beforemagnetic separation in order to block binding of
unstable (low-affinity) Brn3a–DNA complexes. The beads were immediately
washed two timeswith binding buffer to remove the oligonucleotide competitor, and
the remaining bound DNA fragments were eluted from the paramagnetic beads by
incubation in TE buffer containing 1%SDS and 20μg glycogen at 60 °C for 15min.
DNA fragments were recovered by phenol/chloroform extraction followed by
ethanol precipitation.
Selected BAC fragments were ligated into pSTBlue-1, and recombinant
plasmids were used to transform E. coli using the Acceptor Vector Kit
(Novagen). Positive colonies were isolated using blue/white selection and
plasmid DNAwas prepared for sequencing. Insert sequences were aligned with
the BAC sequence using BLAST to determine the location of the selected
fragments containing Brn3a binding sites.
In a prior study using CoSS screening (Trieu et al., 1999), we identified
clustered Brn3a binding sites at −5,633 relative to the start of transcription as the
highest affinity sites within 11 kb of the Pou4f1 transcription start site. These
sites, which deviate slightly from the optimal consensus, were not selected by
the more stringent protocol described here. The principal difference in the
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S-transferase (GST) fusion protein for the selection process. Fusion to GST
stabilizes the interaction between the POU domain and DNA, resulting in the
retention of lower affinity complexes (Rhee et al., 2001). In the current study,
full-coding Brn3a without a GST moiety was employed.Results
Brn3a is a direct repressor of bHLH transcription factors
In the absence of Brn3a, sensory neurons exhibit abnormal
axon growth, fail to correctly innervate their target fields, and
undergo abnormal cell death in late gestation. In the trigeminal
ganglion, these defects are accompanied by significant changes
in the expression of multiple genes, including both increased
and decreased transcripts (Eng et al., 2004). These changes in
gene expression may be either mediated directly by Brn3a, or
indirectly by several other transcription factors which exhibit
altered expression in Brn3a knockout mice.
In order to better understand the relationship of Brn3a DNA
binding to transcriptional regulation, we employed chromatin
immunoprecipitation (ChIP) in embryonic sensory neurons to
map the direct sites of Brn3a interaction with selected
downstream genes. For this analysis, we chose microdissected
embryonic day 13.5 (E13.5) trigeminal ganglia because at this
stage the developing sensory neurons are relatively homo-
geneous with respect to the expression of Brn3a. At E13.5, a
majority of cells in the trigeminal express Brn3a, and relatively
few express the glial marker Sox10 (Fig. 1), while at E16.5 and
later stages, differentiating glia, which may contribute to
background in this assay but not to Brn3a ChIP signal, are far
more numerous (data not shown).Fig. 1. Cellular expression of Brn3a in the embryonic trigeminal ganglion.
Guinea pig anti-Sox10 (Maka et al., 2005) and rabbit anti-Brn3a were used to
perform immunofluorescence as previously described (Fedtsova and Turner,
1995). (A) In the E13.5 trigeminal, the majority of cells are Brn3a-expressing
neurons. The relatively small population of differentiating glia present at this
stage are identified by small nuclei and the expression of Sox10. (B–E) An
enlarged view shows mutually exclusive cellular expression of Brn3a and Sox10
(boxed area in panel A). Occasional cells express neither antigen (arrows, panel
E) and may represent nucleated blood cells.For screening assays of Brn3a binding to target gene loci,
real-time PCR primer sets were designed at intervals of 0.5–
1 kb spanning a region of approximately 40 kb for each gene, a
strategy we refer to as locus-wide chromatin immunoprecipita-
tion (locus-ChIP). To verify the results of the initial locus-ChIP
screens, multiple primer pairs were subsequently designed to
confirm Brn3a binding at specific sites. For each target gene, the
region examined spans the entire transcription unit, plus
extended 5′- and 3′-flanking regions. The rationale for screen-
ing entire loci in this manner was 2-fold. First, although the
Brn3a consensus binding sequence has been determined in
vitro, the extent to which the site may deviate from the
consensus and still permit binding in vivo is unknown, and the
locus-ChIP method is unbiased with respect to the sequence of
the occupied site. Second, enhancer elements are often located
at a considerable distance from the transcription units they
regulate, and we did not want to arbitrarily restrict the analysis
to the region immediately adjacent to the transcription start site.
Prior work has shown that three bHLH transcription factors
exhibit significantly increased expression in the trigeminal
ganglia of mid-gestation Pou4f1 knockout embryos, including
NeuroD4 (Math3, 8-fold increase), NeuroD1 (3-fold), and Msc
(Musculin, MyoR, 7-fold, Eng et al., 2004). For this reason, the
locus-ChIP method was first applied to these gene loci, using
pools of 60 microdissected E13.5 trigeminal ganglia as starting
material for the assay. Fig. 2 shows the result of locus-ChIP
screening of the NeuroD4 locus, revealing two positions in the
locus occupied by Brn3a in vivo, in the 5′-flanking region at
−12,996 relative to the start of transcription, and to a region
within the first intron at +4410. Sequence analysis of the
regions identified by ChIP confirmed the presence of Brn3a
consensus sites at both locations. Kinetic electrophoretic
mobility shift assays (EMSAs, Materials and methods) were
then performed to demonstrate that Brn3a forms stable
complexes with each of these sites in vitro (Fig. 2B).
Each of the binding sites identified in the NeuroD4 locus
contains a partial duplication of the Brn3a consensus sequence,
indicating the possibility of multimeric Brn3a binding. In order
to assay the stoichiometry of Brn3a association with each site,
we compared the EMSA complexes formed by Brn3a bound to
the NeuroD4 sites to those formed with a consensus monomeric
Brn3a binding sequence (b3s1; Gruber et al., 1997; Rhee et al.,
1998). Each of the NeuroD4 binding sites forms a highly stable
complex with multiple Brn3a molecules (Fig. 2C), consistent
with prior evidence that Brn3a exhibits cooperative homo-
dimerization on extended sites (Rhee et al., 1998). The
identification of in vivo Brn3a binding sites at the NeuroD4
locus, in conjunction with increased NeuroD4 expression in the
absence of Brn3a, demonstrates that Brn3a is a direct repressor
of NeuroD4 expression in the developing trigeminal ganglion.
Locus-ChIP screening of the NeuroD1 locus revealed a
broad area of enrichment beginning approximately 7 kb
upstream from the start of transcription, and extending through
the end of the transcribed region of the gene (Fig. 3A). Five sites
were identified in NeuroD1 5′-flanking region that contained a
Brn3a consensus or variant consensus site. The maximum
enrichment occurred in the 3′ UTR of the NeuroD1 gene,
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contrast to NeuroD4 and NeuroD1, a locus-ChIP survey of the
Msc locus from −20 kb to +20 kb did not reveal any occupied
Brn3a binding sites (Fig. 3B). Thus, it is likely that increased
expression of Musculin in the trigeminal ganglia of Pou4f1
knockout mice is mediated by an indirect mechanism, although
is also possible that Brn3a may regulate the expression of
Musculin by direct interaction with binding sites outside the
region examined.
Direct autoregulation by Brn3a
In prior work, we have shown genetic evidence that Brn3a
attenuates its own expression by autoregulation, mediated by a
cluster of Brn3a binding sites ∼5 kb upstream from the start of
transcription (Trieu et al., 1999, 2003). These binding sites reside
within a well-characterized Pou4f1 enhancer which regulates the
expression of Brn3a in the sensory PNS (Eng et al., 2001), but thesequences targeting Brn3a expression to the CNS have not been
identified. To screen for additional Brn3a binding sites in the
extended Pou4f1 locus that may mediate autoregulation in the
CNS, we employed an in vitro immunoprecipitation method
termed complex stability screening (CoSS; Trieu et al., 1999). To
apply the CoSS method to the Pou4f1 locus, a BAC clone
containing 188 kb of genomic DNA encompassing the Pou4f1
gene and surrounding sequences was sheared into 200–500 base
pair fragments by sonication, then incubated with recombinant
Brn3a protein. Following this binding reaction, the Brn3a–DNA
complexes were incubated briefly in the presence of excess
competitor oligonucleotide containing a consensus Brn3a site,
followed by separation of the remaining stable complexes using an
immobilized anti-Brn3a antibody (Materials and methods). Under
these conditions, only fragments containing the highest affinity
binding sites in the BAC clone are retained.
The CoSS-selected DNA fragments were ligated into a cloning
vector for sequencing, and approximately 130 cloned fragments
were mapped onto the complete sequence of the extended Pou4f1
locus (Fig. 4A). In nearly every case in which multiple selected
fragments mapped to the same region of the locus, a Brn3a
consensus binding site was identified in the region common to the
fragments. However, this high-stringency screen did not select the
autoregulatory sites approximately 5 kb upstream from the Pou4f1
transcriptional start site identified by lower stringency screening
and genetic analysis in prior studies (Trieu et al., 1999, 2003). To
resolve this possible divergence in results, EMSAs were
performed on the Brn3a sites identified in both screens in orderFig. 2. Brn3a is a direct regulator of the NeuroD4 gene in the embryonic
trigeminal ganglion. (A) ChIP analysis of Brn3a binding to the NeuroD4 locus
in E13.5 ganglia. Sixty-three primer pairs were used in real-time PCR assays to
screen the locus from −20 kb to +20 kb relative to the transcriptional start site
(Supplementary Table 3). The fold enrichment of the selected versus unselected
chromatin was normalized to a control value of one (C on y-axis), based on the
signal the Alb-1 locus (Materials and methods). The average enrichment from
three selection experiments using independent pools of ganglia is shown for
each primer pair. Sequence analysis of the regions of maximum ChIP selection
revealed consensus Brn3a binding sites at −12,996 and +4410 relative to the
start of transcription (vertical red lines). Differences between the ChIP selection
peaks at −12996 and +4410 and Alb-1 locus control values were highly
significant (p=0.003 and p=0.002, respectively, Materials and methods). (B)
Kinetic EMSA assays were used to determine the relative stability of Brn3a
binding to the sites identified by ChIP. In these assays, Brn3a protein was
allowed to bind radiolabeled oligonucleotides, and the complexes were then
incubated in the presence of an excess of specific competitor oligonucleotide
(Materials and methods). The amount of complex remaining after 5 and 20 min
was used to determine the half-life of each complex. The relative first-order
dissociation rates of the Brn3a–DNA complexes observed in these assays allow
a rapid approximate comparison of relative site affinity (Gruber et al., 1997;
Trieu et al., 1999). Multiple complexes were observed due to size heterogeneity
of the expressed protein and multimeric binding to overlapping recognition sites
(arrows). NP, no Brn3a protein; NC, no competitor; 5 min, 5-min incubation
with competitor; 20 min, 20-min incubation with competitor. (C) Oligonucleo-
tide probes containing a previously determined optimal monomeric consensus
binding site (Cons; Gruber et al., 1997) and the Brn3a recognition sequences in
the NeuroD4 locus were used to demonstrate the interaction of multimeric
binding of Brn3a to the NeuroD4 sites. Supershifts with Brn3a antibody (Ab)
demonstrate that all major complexes contain Brn3a. NP, no Brn3a protein; B3,
Brn3a protein containing cell lysate added; Ab, cell lysate plus Brn3a antiserum;
Mono, monomeric Brn3a complexes; Multi, multimeric Brn3a complexes.
Fig. 3. ChIP analysis of Brn3a binding to the NeuroD1 and Msc loci in E13.5
trigeminal ganglia. (A) In vivo binding of Brn3a to the NeuroD1 locus. A peak
of enrichment in a region of the 3′ UTR conserved between the mouse and
human genomes includes a Brn3a consensus site at +2973 (difference from
controls, p=0.008). The region extending from −16 kb to −11 kb consists of
repetitive sequence and was not included in the analysis. ChIP primer pairs used
for the NeuroD1 locus appear in Supplementary Table 4. (B) Brn3a ChIP
analysis of the Msc locus from −20 kb to +20 kb relative to the start of
transcription reveals no significant in vivo binding of Brn3a. Average
enrichment values from three independent ChIP assays are shown for both
loci. Primer pairs used in ChIP assays of theMsc locus appear in Supplementary
Table 5.
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Brn3a bound to each site (Fig. 4B). These results confirm the
presence of multiple stable Brn3a binding sites in the extended
Pou4f1 locus, and also show that the sites within the Pou4f1au-
toregulatory region (−5633) have suboptimal binding, suggesting
that the in vitro affinity of Brn3a for its cognate sites may not be
the best predictor of biological function.
In order to determine the relationship between in vitro
binding and in vivo occupancy of the sites identified within the
Pou4f1 locus, we next used locus-ChIP to screen the Pou4f1
locus for Brn3a binding from −75 kb to +85 kb in E13.5
trigeminal ganglia (Fig. 4C). A total of 103 primer pairs were
used in the assay, including those designed to confirm binding
sites detected in the in vitro screen. These results demonstrate in
vivo Brn3a binding to the autoregulatory enhancer at −5633relative to the transcriptional start site, and to multiple sites
identified 3′ to the Brn3a transcription unit.
Taken together, data from in vitro selection assays, in vivo
ChIP assays, and EMSAs for Brn3a binding sites at the Pou4f1
locus suggest that specificity conferred by the local DNA
sequence is not sufficient to explain the interaction of Brn3a
with chromatin in vivo. Instead, sites in the distal 5′ region of
the Pou4f1 BAC appear to exhibit low occupancy relative to
their in vitro binding, exemplified by the very stable site at
−58,080 which was selected most frequently in vitro, but is
weakly bound in vivo (Fig. 4D). Conversely, sites within the
genomic region from approximately −10,000 to +3000 relative
to the start of transcription, encompassing the Pou4f1 sensory
enhancer, autoregulatory region, transcriptional start, 5′ UTR,
and first intron, are more highly occupied by Brn3a protein than
would be predicted based on in vitro binding.
Brn3a binding to target gene loci in vivo correlates with
interspecies conservation and specific histone modifications
In order to better understand the context-dependent binding
of Brn3a, we examined the conservation of the identified
binding sites between mouse and human genomic sequences
and the specific modifications of histones across the gene loci
of Brn3a and its downstream targets. Sequence conservation
between species is a hallmark of functional regulatory
regions, and local histone modifications have also been
shown to play an important role in the regulation of gene
expression (Margueron et al., 2005). Specifically, acetylation
of the N-terminal tail of histone H3, associated with other
modifications, is thought to induce an open conformation of
chromatin that is accessible to the ubiquitous transcriptional
machinery (Eberharter and Becker, 2002; Struhl, 1998).
Although histone acetylation is generally associated with the
promoter regions of transcribed genes, several examples
indicate that tissue-specific distal regulatory regions may also
be acetylated (Bulger, 2005).
Comparison of the mouse and human genomic loci for the
downstream bHLH targets of Brn3a regulation and the Pou4f1
locus itself reveal that nearly all of the occupied Brn3a binding
sites reside in regions of highly conserved sequence (Figs. 5B,
C, and 6). The peak of Brn3a ChIP selection in the NeuroD1
locus (+2973) resides in a highly conserved region of the 3′
untranslated portion of this gene. Similarly, in the NeuroD4
locus, the selected site in the first intron (+4410) resides in a
highly conserved region. However, no region of extended
homology could be identified for the distal NeuroD4 site
(−12,996). Within the regions of extended conservation
containing the Brn3a binding sites at the NeuroD1 and
NeuroD4 loci, the specific sequence of the consensus Brn3a
binding sites are also fully conserved (Supplementary Fig. 3).
Occupied Brn3a binding sites within the Pou4f1 locus
showed a similar degree of interspecies conservation. The
Brn3a autoregulatory enhancer region (−5633) has been
previously shown to encompass a region of 244 bp which is
100% conserved between mouse and human (Trieu et al., 2003),
including five variant Brn3a binding sites. Alignment of mouse
Fig. 4. Brn3a binding to the Pou4f1 locus in vitro and in embryonic trigeminal ganglia. (A) Complex stability screening of a 188-kb BAC encompassing the Pou4f1
locus. BAC DNAwas sheared by sonication and selected using recombinant Brn3a protein (Materials and methods). Fragments were ligated into a cloning vector, and
128 independent clones were sequenced. The histogram indicates the number of fragments identified within each 2000 base pair interval of the BAC. In nearly every
case, BAC regions identified by multiple clones contained Brn3a consensus binding sites, as indicated on the map of the Pou4f1 locus. In a prior study (Trieu et al.,
1999), lower stringency screening of a smaller region of the Pou4f1 locus identified Brn3a binding sites of moderate affinity in the autoregulatory enhancer region
(−5633). The higher stringency screening of a much larger genomic clone shown here did not identify these sites, but revealed several higher affinity sites in other
regions of the locus. Within the region encompassed by this BAC, two transcripts of unknown function have been identified, 2610206B13Rik and D130079A08Rik.
These transcripts extend from −54,719 to −9586 and +8795 to +23,049 relative to the start of Brn3a transcription, respectively, and are transcribed on the same strand.
D130079A08Rik was identified from ESTs cloned from mouse spinal ganglion, and it is unclear whether these sequences represent an independently transcribed gene,
or alternate Pou4f1 transcripts. (B) Kinetic EMSA analysis of Brn3a binding to identified Brn3a binding sites. NP, no Brn3a protein; NC, no competitor; 5 min, 5-min
incubation with competitor; 20 min, 20-min incubation with competitor. (C) ChIP analysis of the Pou4f1 locus using 103 primer pairs to screen an ∼160-kb genomic
region for in vivo binding of Brn3a. Multiple areas of enrichment were identified including the Brn3a autoregulatory site cluster at −5633 (difference from controls,
p=0.003) and four areas 3′ to the transcription unit at +7093 (p=0.0007), +43,473 (p=0.007), +51,848 (p<0.0001), and +78,456 (p=0.01). Binding at −58,080 did
not reach significance (p>0.01). Data are average values from three ChIP assays using independent pools of E13.5 trigeminal ganglia. Primer pairs used in ChIP assays
of the Pou4f1 locus appear in Supplementary Table 6. (D) A comparison of in vitro affinity and in vivo binding suggests that Brn3a binding sites 5′ to the transcription
unit are occupied less often than expected based on affinity, sites in the vicinity of the autoregulatory enhancer are occupied more often than expected, and sites 3′ to the
transcription unit are occupied approximately in proportion to affinity.
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binding sites in the 3′ flanking region of the Pou4f1 locus
(+7093, +43,473, +51,848, +78,456) also reside in islands of
highly conserved sequence and exhibit conservation of the
Brn3a binding sites within these regions (Figs. 5B and C and
Supplementary Fig. 3).To assay chromatin modification in sensory neurons, we
performed ChIP analysis of the Pou4f1 locus and target gene
loci using an antibody recognizing acetylated histone H3
(Materials and methods). As described for locus-ChIP assays
using anti-Brn3a antibodies, these experiments were performed
using microdissected E13.5 trigeminal ganglia as starting
Fig. 5. Markers of chromatin modification at the Pou4f1 locus. (A) Locus-ChIP assays were performed for acetylated histone H3 over an ∼160-kb region
encompassing the Pou4f1 locus in E13.5 trigeminal ganglia. Data show average enrichment from two sets of assays using separate pools of ganglia. H3 acetylation is
increased within an ∼15-kb region including the autoregulatory domain, transcriptional start site, and primary transcript. The area of enrichment at −53,620 is closely
associated with the transcription start site of an adjacent gene, 2610206B13Rik, and does not coincide with the Brn3a binding site at −58,080 (vertical red bar, dashed
line). The fold enrichment of the selected versus unselected chromatin was normalized to a control value of one (C on y-axis), based on the signal from the Alb-1 locus
(Materials and methods). (B) Detailed map of histone H3 acetylation within a 25-kb region containing the Pou4f1 transcription unit. A region of increased acetylation
encompasses the Brn3a autoregulatory site cluster at −5633, the transcription start site, and extends beyond the 3′ end of the transcript to include the Brn3a binding site
at +7093. AVISTA plot of mouse–human homology within the locus indicates that regions of enhanced acetylation are correlated with areas of conserved sequence.
(C) Detailed map of histone-H3 acetylation from a 4-kb region containing the in vivo Brn3a binding site at +78,456. The region of moderately enhanced acetylation
associated with this site also shows sequence conservation between the mouse and human genomes. (D) Locus-ChIP of the Pou4f1 locus using antibodies to
dimethylated H3-K4. The patterns of H3 acetylation and H3-K4 dimethylation are highly congruent.
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locus from −75 kb to +85 kb relative to the transcription start
site (Fig. 5A).Enrichment values for most of the region examined
approached background, indicating that chromatin is not
hyperacetylated over most of the extended Pou4f1 locus.
Fig. 6. Acetylated histone H3 ChIP assays of the NeuroD4 and NeuroD1 loci.
(A) Map of histone H3 acetylation of the NeuroD4 locus from −20 kb to +20 kb
relative to the start of transcription, revealing three peaks of acetylation that
encompass the start of transcription and the two identified in vivo Brn3a binding
sites. (B) Histone H3 acetylation of the NeuroD1 locus. A broad peak of
acetylation encompasses the NeuroD1 transcription unit extending from
approximately −5 kb to +7 kb relative to the transcription start site, including
the in vivo Brn3a binding site at +2973. Panels A and B both show average
enrichment values from two ChIP assays using separate pools of E13.5
trigeminal ganglia. In vivo Brn3a binding sites are represented by vertical red
bars.
711J. Lanier et al. / Developmental Biology 302 (2007) 703–716However, a major area of increased H3 acetylation extends from
approximately −8000 to +10,000 relative to the start of
transcription (Fig. 5B). Examination of this region at higher
resolution (Fig. 5B) reveals discrete peaks of acetylation at the
Pou4f1 autoregulatory region (−5.5 kb) and at the transcription
start site, while the intervening region from −4 kb to −2 kb is
much less acetylated. Significant acetylation also occurs 3′ to
the transcription unit, encompassing an occupied Brn3a binding
site identified at +7093. In the far distal part of the locus, a
relatively weak but significant area of acetylation was identified
encompassing an occupied Brn3a binding site located at+78,456 (Fig. 5C). Finally, a hyperacetylated region was
identified at −53,620 relative to the Pou4f1 transcription start
site, which corresponds precisely to the transcription start site of
an adjacent gene of unknown function, 2610206B13Rik. This
peak of acetylation does not coincide with the identified Brn3a
binding site at −58,080, which exhibits very stable binding in
vitro, but exhibits low occupancy in vivo.
We then examined histone H3 acetylation at the genomic loci
of the bHLH factors directly regulated by Brn3a (Fig. 6). The
NeuroD4 locus is characterized by increased acetylation from
approximately −2000 to +5000, with maximal enrichment
observed near the transcription start site. A distinct peak of
acetylation encompasses the in vivo Brn3a binding site located
within the NeuroD4 first intron at +4410. An additional minor
acetylation peak occurs approximately 13 kb upstream of the
transcription start site, corresponding with another in vivo
Brn3a binding site at −12,995.
Histone H3 acetylation of the NeuroD1 locus extends from
approximately −5000 to +6000 relative to the transcriptional
start site. H3 acetylation at the NeuroD1 locus exceeded that at
the NeuroD4 locus, consistent with the higher expression of
NeuroD1 in wild-type ganglia (Eng et al., 2004). The region
of acetylation corresponds with the area of enrichment observed
in locus-ChIP analysis using α-Brn3a antibody, and maximal
acetylation was observed near the transcription start site and at
the identified Brn3a binding site at +2973.
In addition to acetylation of histone H3, dimethylation of H3
lysine 4 (K4) has been shown to mark actively and potentially
transcribed genes in yeast and higher eukaryotes (Santos-Rosa
et al., 2002; Schneider et al., 2004; Schubeler et al., 2004).
Therefore, in order to further define the relationship between
markers of chromatin structure and Brn3a binding, we
performed dimethyl H3-K4 locus-ChIP analysis of the relevant
genes in embryonic trigeminal ganglia. At the Pou4f1 locus
(Fig. 5D), the pattern of H3-K4 dimethylation is remarkably
similar to that of H3 acetylation, including significant
enrichment in the autoregulatory enhancer region, the transcrip-
tion start site, and an occupied Brn3a binding site identified at
+7093. The NeuroD4 and NeuroD1 genes also reveal patterns
of H3-K4 dimethylation that closely parallel H3 acetylation at
these loci (Supplementary Fig. 2), leading to the conclusion that
these marks reflect a similar state of chromatin, associated with
Brn3a binding.
Brn3a is excluded from the regulatory regions of genes not
expressed in sensory ganglia
Taken together, the locus-ChIP data for Brn3a and its direct
targets suggest that in vivo binding of Brn3a is highly context
dependent, and that site occupancy is predicted by occurrence of
the sites in conserved regulatory regions which are also H3-
acetylated and K4-dimethylated in trigeminal neurons. This
observation leads to the prediction that Brn3a binding sites in
the regulatory regions of genes which are never expressed in
developing sensory neurons, and thus reside in regions of
silenced chromatin, will not be occupied in vivo regardless of
affinity. To test this hypothesis, we identified potential Brn3a
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database containing upstream sequences of 14,963 well-
characterized transcripts (MM5 upstream2000, UCSC Genome
Bioinformatics). We then used microarray expression data from
E13.5 (Eng et al., 2004) and adult (NCBI Gene Expression
Omnibus) trigeminal ganglia to identify a subset of these genes
that are not expressed in trigeminal neurons.
The bioinformatic search of the promoter database identified
several hundred promoters containing variants of the Brn3a
consensus sequence. From this set, 28 sites with high sequence
similarity to the occupied sites in the Pou4f1 and NeuroD4promoters were analyzed for Brn3a binding using kinetic
EMSA assays. Using the dissociation half-lives of the
complexes of these sites with Brn3a, they were categorized as
exhibiting low, moderate, high, or very high stability. In these
assays, the monomeric Brn3a consensus site exhibited moderate
stability, and all of the sites with “high” or “very high” stability
were characterized by the association of multiple Brn3a
molecules with the site. Extensive prior studies using cell
transfection and transgenic assays have demonstrated the ability
of sites with these monomeric and dimeric motifs to mediate the
transcriptional effects of Brn3a (Gruber et al., 1997; Rhee et al.,
1998; Trieu et al., 1999, 2003). Fig. 7A shows representative
EMSAs of oligonucleotides containing a consensus monomeric
Brn3a binding site and binding sites from the promoters of two
of the identified genes, Sema3e and Ngp.
Nine of the promoters which contain Brn3a binding sites, but
are transcriptionally silent in the trigeminal ganglion, were
selected for ChIP analysis of histone acetylation and in vivo
Brn3a binding (Fig. 7), using PCR amplicons near each of the
identified binding sites. Fig. 7B compares H3 acetylation at
these sites with sites in regulatory regions within the Pou4f1
locus. As predicted, H3 acetylation at these non-expressed
genes is very low in comparison with the promoter/enhancer
regions of the Pou4f1 locus and the other expressed genes
examined in this study, and in most cases approaches the
baseline set by amplicons in the albumin locus. ChIP assays for
Brn3a binding at these sites were also uniformly negative (Fig.
7C). Thus, these sites are unoccupied in vivo despite the fact
that their sequence and in vitro Brn3a binding characteristics are
very similar to the occupied sites in the Pou4f1 and NeuroD4
regulatory regions, providing a striking confirmation of the
context-dependent binding of Brn3a.Fig. 7. Analysis of Brn3a binding sites identified in the promoters of genes not
expressed in the developing trigeminal ganglion. (A) Representative kinetic
EMSA results for a Brn3a consensus site, and Brn3a sites identified in the
Sema3e and Ngp promoters. For all sites tested, dissociation half-lives of
Brn3a–DNA complexes were estimated based on first order kinetics (Materials
and methods) and were categorized as low, t1/2=0–2 min; moderate, t1/2=2–
4 min; high, t1/2=4–15 min; and very high, t1/2>15 min. A single consensus
Brn3a binding site exhibits moderate stability in this assay because the sites with
the highest stability are characterized by multimeric binding. NP, no protein;
NC, no competitor. Sites tested in panels A–C were identified within 2 kb of the
transcriptional start of the following genes: gastric inhibitory polypeptide, Gip;
placental lactogen-I beta, Plib; semaphorin 3E, Sema3e; RNA binding motif,
single-stranded interacting protein 2, Rbms2; transcript of unknown function,
D8Bwg1414e; aldo-keto reductase family 1, member C13, Akr1c13; caspase 6,
Casp6; x-linked lymphocyte-regulated complex, Xlr; and neutrophilic granule
protein, Ngp. Gene map locations appear in Supplementary Table 1. (B) ChIP
analysis of histone H3 acetylation at silent promoters containing Brn3a binding
sites. Fold enrichment for each promoter was determined using one or two real-
time PCR primer pairs hybridizing near the binding site identified in the EMSA
assays. Assays for sites in the Pou4f1 locus (Fig. 5A) are shown for comparison.
(C) ChIP analysis of Brn3a binding at silent promoters. Assays for sites in the
Pou4f1 locus (Fig. 4C) are shown for comparison. No significant Brn3a
binding was observed at any of the promoters of genes not expressed in the
trigeminal. For panels B and C, the enrichment values for three ChIP assays on
independent samples were used for each primer pair. Enrichment values for
multiple primer pairs targeting the same promoter were averaged, and bars show
mean+SEM of three or six assays.
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Brn3a is a direct repressor of bHLH genes and its own
autoregulatory enhancer
In the present study, we have used locus-wide ChIP assays to
examine the direct interaction of Brn3a with four of its
regulatory targets, the bHLH genes NeuroD4, NeuroD1, and
Msc, and the Pou4f1 gene itself. These bHLH transcription
factors were selected from among the 85 transcripts we have
previously shown to exhibit >2-fold changed expression in the
developing trigeminal ganglia of Pou4f1 null mice (Eng et al.,
2004) because they are likely to be high in the regulatory
hierarchy that leads to the Brn3a null phenotype. ChIP assays
were performed with microdissected embryonic trigeminal
ganglia, which provide a relatively homogenous source of post-
mitotic Brn3a-expressing neurons. Although the results of ChIP
assays may in principle be quantitated either with PCR-based
methods or with microarrays (ChIP-on-chip; Blais et al., 2005;
Carroll et al., 2005; Ren et al., 2002), here the analysis was
limited to PCR-based methods, because the samples obtained
from embryonic ganglia provide approximately 100-fold less
starting material than that required by established ChIP-on-chip
protocols.
Two refinements in PCR-quantitated ChIP were incorporated
into the methods used in this study. First, real-time PCR with
fluorimetric detection was employed, and the immunoprecipi-
tated chromatin fragments were assayed by the cycle-threshold
difference method (Ct difference; Livak and Schmittgen, 2001).
This method allows each assay of ChIP selected DNA to be
compared directly to an unselected sample using the same set of
primer pairs, such that the observed enrichment for a given set
of primers is highly likely to be a specific effect of the antibody
selection process. The second refinement was the application of
many sets of PCR primers arrayed across an extended gene
locus (locus-ChIP). Locus-ChIP has the advantage of rapidly
identifying regions of transcription factor binding or chromatin
modification, yielding a map similar to a tiled array (Ciccone et
al., 2004; Litt et al., 2001). In addition, multiple primer pairs can
be designed to a particular region of interest to independently
replicate significant findings. Finally, unlike ChIP assays
targeting specific predicted binding sites or promoter regions,
locus-ChIP analysis is independent of any assumption about
where protein–DNA interactions will occur.
The results of these experiments demonstrate that Brn3a is a
direct repressor of NeuroD4 and NeuroD1 in the developing
trigeminal ganglion. Combined with the altered expression of
other transcripts in the sensory ganglia of Pou4f1 null mice
(Eng et al., 2004), these results suggest that a major function of
Brn3a in post-mitotic trigeminal neurons is to terminate the
expression of genes characteristic of earlier developmental
phases, and also to repress genes normally expressed in the
hindbrain but not in the sensory ganglia. In contrast to NeuroD4
and NeuroD1, no evidence could be found for Brn3a binding at
the Msc locus. Despite these results, it is possible that Brn3a
acts directly to repress the Msc locus at regulatory sites which
lie outside the 40-kb region examined by locus-ChIP, or theMscgene may be activated indirectly in Pou4f1 null mice by other
transcription factors which show markedly increased expression
in the absence of Brn3a (Eng et al., 2004).
Direct regulation of the Pou4f1 autoregulatory enhancer was
also verified by locus-ChIP, although the occupancy of the
autoregulatory sites appears to be significantly less than those of
the NeuroD4 locus. Relatively weak repression of the
autoregulatory enhancer is consistent with the quantitative
expression of NeuroD4 and Brn3a mRNA in the E13.5
trigeminal ganglion, in that expression from the NeuroD4
locus is repressed to almost undetectable levels by Brn3a (Eng
et al., 2004) whereas expression from the Pou4f1 locus clearly
continues throughout development, and is only modulated by
autoregulation via relatively weak binding sites (Trieu et al.,
2003, 1999). Although no definitive conclusion can be drawn
from these examples, it is plausible that different binding site
affinities and site occupancy in target gene loci may be a general
mechanism for controlling the extent of repression by Brn3a.
Context-dependent DNA binding by Brn3a
In general, tissue-specific transcription factors appear to
have many more potential genomic binding sites than the
observed number of downstream genes in a specific cell type.
Most monomeric transcription factors have DNA recognition
sites with a complexity equivalent to 4–5 unique base pairs,
leading to an expected occurrence in vertebrate genomes of
>106. In many cases, binding specificity is increased by homo-
or heterodimerization, and in the case of the POU domain
family this is achieved by the integration of two DNA binding
domains into a single transcription unit (Phillips and Luisi,
2000). Dimeric transcription factors recognize extended sites,
but given the inherent flexibility in the DNA recognition
properties of most of these proteins, the specificity of binding
rarely exceeds approximately 8 unique bases, yielding 104–105
predicted recognition sites. Consistent with these general
predictions, we performed a compete search of mouse
chromosome 4, which contains 5.94% of the genome, for the
consensus Brn3a binding site ATAAA/TTAAT (Gruber et al.,
1997), revealing 10,738 occurrences of this motif. Extrapolating
from this search to the entire genome suggests that there are
greater than 105 potential genomic Brn3a binding sites, and
given that some variation in the consensus is permitted, this is
likely to be an underestimate (calculations appear in Supple-
mentary data).
In contrast, recent micro- and macroarray studies which have
analyzed global changes in gene expression in mice with
mutations of neural transcription factors have identified much
smaller sets of regulated genes. In the developing retina,
microarray analysis has revealed 16 targets of the homeodomain
factor Crx (Livesey et al., 2000), and 87 transcripts regulated by
Brn3b (Mu et al., 2004). In the embryonic cerebellum, analysis
of mice with mutations of the orphan receptor RORa revealed
36 significantly changed transcripts, using somewhat less
stringent criteria than the retinal studies (Gold et al., 2003). In
the developing trigeminal ganglion, 85 transcripts have been
identified which exhibit >2-fold change in the absence of Brn3a
714 J. Lanier et al. / Developmental Biology 302 (2007) 703–716(Eng et al., 2004). Although none of these studies achieved
genome-wide coverage of potentially regulated genes, it is clear
that the number of transcripts with altered expression is far
fewer than the number of potential recognition sites for the
transcription factors examined.
These observations imply that the regulatory activity of
neuron-specific transcription factors will be highly dependent
on the genomic context of their binding sites. In principle, this
could be achieved by either of two mechanisms. First, a
transcription factor might be bound to all of its genomic sites in
relation to their intrinsic affinity but have context-dependent
transcriptional activity. In this model, the transcriptional activity
of the bound factor might require that its binding site be located
proximal to an active promoter, or adjacent to the binding sites
for other factors required to make up an active enhancer/
repressor unit. Second, the activity of a factor might be
restricted at the level of DNA binding, such that only a fraction
of its potential sites are occupied in vivo. This could also be due
to a requirement for adjacent sites for other regulators that
modulate binding, or because of alterations in chromatin
structure which either exclude or permit interaction of the
factor with its target sites. The examples cited here strongly
suggest that the context-dependent activity of Brn3a is regulated
at the level of DNA binding. This is suggested by the variability
of site occupancy across the Brn3a locus, and confirmed by the
observation that sites identified in the promoter regions of genes
which are silent in sensory ganglia, but matched for sequence
and in vitro affinity to known Brn3a-occupied sites, are not
occupied in vivo.
Several determinants are likely to affect context-dependent
DNA binding by Brn3a. Two features that strongly correlate
with site occupancy in Brn3a target gene loci are the presence of
sites in non-coding regions, which show high conservation
between the mouse and human genomes, and the localization of
sites in regions of H3-acetylated and H3-K4 dimethylated
chromatin. Interspecies conservation in non-coding sequence is
a recognized hallmark of regulatory domains (Xie et al., 2005).
The regions of mouse–human homology identified by Brn3a
binding include conservation of the consensus Brn3a binding
sites, but also extend into adjacent regions, consistent with
Brn3a binding within cis-regulatory modules that integrate
inputs from multiple cellular transcription factors (Howard and
Davidson, 2004; Wenick and Hobert, 2004).
Although less well-recognized, histone modifications may
also be useful markers of functional regulatory domains. H3
acetylation and H3-K4 dimethylation are predictive of regions
of open chromatin structure with active transcriptional or
regulatory activity (Margueron et al., 2005). Although these
histone modifications are best characterized near the promoters
of transcribed genes, there are several precedents for histone
acetylation of distal regulatory regions (Bulger, 2005). In the
present study, Brn3a binding in the Pou4f1 locus, and in the loci
of Brn3a target genes, occurs consistently in regions of H3-
acetylated and H3-K4 dimethylated histones. In contrast, high-
affinity Brn3a sites in deacetylated regions of the Brn3a locus
and in silent, deacetylated gene promoters show low occupancy.
Although these examples are correlative, they suggest thatincreased H3 acetylation and H3-K4 dimethylation may be
useful general markers for the regions of chromatin where
Brn3a may interact.
Because Brn3a binding in vivo is highly associated with
local histone H3 acetylation and H3-K4 dimethylation, it is
logical to consider whether these modifications are partly the
result of Brn3a binding. If Brn3a acted as a transcriptional
activator at target bHLH genes and its own locus, it might
induce these modifications through the recruitment of histone
acetyltransferases and methyltransferases. However, the action
of Brn3a as a repressor at these loci strongly suggests that Brn3a
binding occurs only in the context of a pre-existing permissive
state of chromatin modification, generated and maintained by
other factors.
The correlation of Brn3a binding with histone modification
is consistent with recent findings for other transcription factors.
The most complete studies of this kind in vertebrates have
characterized in vivo CREB binding to its recognition element
CRE. In one study, serial analysis of chromatin occupancy
(SACO) was used to carry out a genome-wide scan for CREB
binding sites in forskolin-stimulated PC12 cells. The sequences
bound by CREB in vivo were highly associated with CpG
islands (Impey et al., 2004). Further work from the same group
demonstrated that CREB occupies CRE-containing promoters
in a cell-type-specific manner, and promoters of four genes with
high CREB occupancy in stimulated PC12 cells also showed
high H3-K4 methylation even in the unstimulated state, but
unoccupied promoters were K4 demethylated (Cha-Molstad et
al., 2004). In another a large scale ChIP study, myc binding to
identified E-box elements demonstrated that E-boxes are much
more likely to be occupied within 2 kb of promoters than in
intergenic regions (Fernandez et al., 2003). In a cell line
inducibly expressing high levels of myc, the E-boxes highly
bound in vivo were associated with H3 acetylation even prior to
myc induction. Myc induction then resulted in additional
acetylation at these sites. Thus, for both CREB and myc, pre-
existing chromatin modifications may influence recognition of
target sequences in vivo.
Taken together, these results suggest two important elements
of context-dependent Brn3a target gene recognition in sensory
neurons. First, Brn3a binding occurs in regions of extended
interspecies conservation, suggesting an interaction between
Brn3a and other transcription factors at these sites. Second,
histone modifications may play a role in the modulation of
Brn3a binding. Unlike the primary genomic sequence, histone
modifications may be cell type specific and influence the
interaction of transcription factors with chromatin in a cell-
specific manner. In future studies, mapping genomic loci for
cell-specific histone modifications, in combination with
analysis of interspecies conservation, may significantly
improve the prediction of functional transcription factor binding
sites.
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